Compounds > ecteinascidin 743
Page last updated: 2024-09-02

ecteinascidin 743 and Bone Marrow Diseases

ecteinascidin 743 has been researched along with Bone Marrow Diseases in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bertulli, R; Casali, PG; D'Incalci, M; Dileo, P; Gescher, A; Grosso, F; Jimeno, J; Piovesan, C; Sanfilippo, R; Stacchiotti, S1
D'Incalci, M1
Albella, B; Bueren, JA; Faircloth, G; Guzmán, C; Jimeno, J; López-Lázaro, L1

Other Studies

3 other study(ies) available for ecteinascidin 743 and Bone Marrow Diseases

ArticleYear
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Dioxoles; Disease-Free Survival; Female; Humans; Liver Diseases; Male; Middle Aged; Premedication; Sarcoma; Steroids; Tetrahydroisoquinolines; Trabectedin

2006
Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:10

    Topics: Antineoplastic Agents, Alkylating; Bone Marrow Diseases; Depsipeptides; Dioxoles; Hematopoietic Stem Cells; Humans; Isoquinolines; Megakaryocytes; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin

2002
In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:10

    Topics: Antineoplastic Agents; Bone Marrow Diseases; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Depsipeptides; Dioxoles; Doxorubicin; Drug Screening Assays, Antitumor; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Isoquinolines; Neoplasms; Peptides, Cyclic; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured

2002